Stock BCRX BIOCRYST PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-16 pm EDT 		5-day change 1st Jan Change
4.61 USD -1.28% Intraday chart for BioCryst Pharmaceuticals, Inc. -3.96% -23.04%
Mar. 12 Transcript : BioCryst Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
Feb. 26 Transcript : BioCryst Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 26, 2024

Business Summary

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with complement-mediated and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

Number of employees: 536

Sales per Business

USD in Million2022Weight2023Weight Delta
Oral Small Molecule and Protein Therapeutics
100.0 %
271 100.0 % 331 100.0 % +22.37%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
87.0 %
-- 288 87.0 % -
Non-United States
11.4 %
-- 38 11.4 % -
Global
1.6 %
271 100.0 % 5 1.6 % -98.00%

Managers

Managers TitleAgeSince
Jon Stonehouse CEO
 Chief Executive Officer 63 06-12-31
Anthony Doyle DFI
 Director of Finance/CFO 44 20-04-01
Michael Jones DFI
 Director of Finance/CFO 54 10-12-31
Ryan Arnold CTO
 Chief Tech/Sci/R&D Officer - 22-02-28
Helen Thackray CTO
 Chief Tech/Sci/R&D Officer 55 19-09-19
Philip George PRN
 Corporate Officer/Principal - 22-08-31
Jinky Ang Rosselli PRN
 Corporate Officer/Principal - 14-12-31
Charles Gayer PRN
 Corporate Officer/Principal 53 15-07-31
Stephanie Angelini HRO
 Human Resources Officer - 18-10-31
Salisa Hauptmann LAW
 General Counsel - 20-12-31

Members of the board

Members of the board TitleAgeSince
Alan Levin BRD
 Director/Board Member 62 20-02-26
Jon Stonehouse CEO
 Chief Executive Officer 63 06-12-31
Vin Milano Milano BRD
 Director/Board Member 60 21-07-25
Stephen Aselage BRD
 Director/Board Member 73 19-01-03
George Abercrombie BRD
 Director/Board Member 69 11-10-09
Nancy Hutson CHM
 Chairman 74 12-01-19
Helen Thackray CTO
 Chief Tech/Sci/R&D Officer 55 19-09-19
Steven Galson BRD
 Director/Board Member 67 21-08-31
Theresa Heggie BRD
 Director/Board Member 63 18-12-02
Amy McKee BRD
 Director/Board Member 52 21-09-19

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 206,149,929 199,798,093 ( 96.92 %) 0 96.92 %

Shareholders

NameEquities%Valuation
Vanguard Fiduciary Trust Co.
8.617 %
17,763,720 8.617 % 90 M $
BlackRock Advisors LLC
8.454 %
17,427,628 8.454 % 89 M $
Avoro Capital Advisor LLC
6.330 %
13,050,000 6.330 % 66 M $
STATE STREET CORPORATION
6.198 %
12,777,003 6.198 % 65 M $
Baker Bros. Advisors LP
4.912 %
10,126,176 4.912 % 51 M $
Braidwell LP
2.774 %
5,718,477 2.774 % 29 M $
Kynam Capital Management LP
2.231 %
4,600,000 2.231 % 23 M $
Deerfield Management Co. LP (Private Equity)
2.202 %
4,539,525 2.202 % 23 M $
Geode Capital Management LLC
2.067 %
4,260,638 2.067 % 22 M $
RP Management LLC
1.866 %
3,846,154 1.866 % 20 M $

Company contact information

BioCryst Pharmaceuticals, Inc.

4505 Emperor Boulevard Suite 200

27703-8457, Durham

+919 859 1302

http://www.biocryst.com
address BioCryst Pharmaceuticals, Inc.(BCRX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Ratings for BioCryst Pharmaceuticals, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
4.67 USD
Average target price
12.2 USD
Spread / Average Target
+161.24%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
BIOCRYST PHARMACEUTICALS, INC. Stock BioCryst Pharmaceuticals, Inc.
-23.04% 963M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.13% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+1.80% 96.56B
ARGENX SE Stock argenx SE
+1.72% 22.61B
BIONTECH SE Stock BioNTech SE
-18.19% 21.18B
GENMAB A/S Stock Genmab A/S
-4.50% 19.07B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.75% 16.53B
BEIGENE, LTD. Stock BeiGene, Ltd.
-25.68% 14.46B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.93% 13.25B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+21.63% 11.1B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BCRX Stock
  4. Company BioCryst Pharmaceuticals, Inc.